PellePharm's Unattributed - II Round

PellePharm raised a round of funding on May 11, 2015.

PellePharm is developing topical patidegib, a first-in-class topical hedgehog inhibitor, to decrease the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients.…

Articles about PellePharm's Unattributed - II Round: